Abstract |
Recently, type I interferons IFN-alpha and IFN-beta (IFN-alpha/beta) have been evaluated in pilot clinical trials for the treatment of active ulcerative colitis. However, the underlying mechanisms that may contribute to a potential therapeutic effect are incompletely understood. A new study in this issue demonstrates a protective role for IFN-alpha/beta, induced by activation of a Toll-like receptor 9-dependent pathway, in a rodent model of experimental colitis.
|
Authors | Stefan Wirtz, Markus F Neurath |
Journal | The Journal of clinical investigation
(J Clin Invest)
Vol. 115
Issue 3
Pg. 586-8
(Mar 2005)
ISSN: 0021-9738 [Print] United States |
PMID | 15765141
(Publication Type: Comment, Journal Article)
|
Chemical References |
- Interferon-alpha
- Interferon-beta
|
Topics |
- Animals
- Clinical Trials as Topic
- Colitis, Ulcerative
(immunology, therapy)
- Humans
- Interferon-alpha
(immunology)
- Interferon-beta
(immunology)
- Intestines
(cytology, immunology, pathology)
|